Resverlogix Corp.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
31.6M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Healthcare
Biotechnology
TSX
Key Financial Metrics
-
Revenue
-7.6M
Net Income
C$-0.03
EPS (Diluted)
-4.4M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-4.2M
Returns & Efficiency
Return on Assets (ROA)
-104.0%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
7.3M
Total Debt
16.5M
Debt to Equity
-
Current Ratio
0.06
Company Info
| Industry | Biotechnology |
| HQ | Calgary, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.resverlogix.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
1,595,832
Shares Sold
0
Total Transactions
8
SEDAR+ Filings
View All Filings1
Annual Reports
19
Quarterly Reports
20
MD&A
77
News Releases
9
Material Changes
14
Governance
39
Certifications
61
Other
●
2018-07-30
Interactive Charts
Company Profile
General Information
| Company Name | Resverlogix Corp. |
| Ticker | RVX.TO |
| Exchange | TSX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Calgary, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.resverlogix.com |
Financial Summary
| Market Cap | 31.6M |
| Revenue | N/A |
| Net Income | -7.6M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.03 |
| Net Margin | N/A |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.